Unusual 11 Mid-Day Movers 11/09: (ZIP) (KYAK) (SCLN) Higher; (GRPN) (DTSI) (RNDY) Lower
Tweet
Share
E-mail
Get Alerts ZIP Hot Sheet
Join SI Premium – FREE
Zipcar, Inc. (Nasdaq: ZIP) % HIGHER; reported Q3 EPS of $0.10, $0.10 better than the analyst estimate of $0.00. Revenue for the quarter came in at $78.2 million versus the consensus estimate of $73.02 million. Sees Q4 2012 revenue of $67-$71 million, versus the consensus of $69.3 million. Also sees FY2012 revenue of $275-$279 million, versus the consensus of $274.63 million.
Kayak Software Corp. (Nasdaq: KYAK) 27.1% HIGHER; will be acquired by priceline.com (Nasdaq: PCLN) for $40 per share.
Groupon (Nasdaq: GRPN) 27.0% LOWER; reported Q3 EPS of $0.00, $0.03 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $568.6 million versus the consensus estimate of $590.12 million. Sees Q4 2012 revenue of $625-675 million, versus the consensus of $633.87 million.
DTS, Inc. (Nasdaq: DTSI) 27.0% LOWER; reported Q3 EPS of ($0.61), $0.68 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $22.2 million versus the consensus estimate of $24.97 million.
Sciclone Pharmaceuticals, Inc. (Nasdaq: SCLN) 23.3% LOWER; reported Q3 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $40.7 million versus the consensus estimate of $44.8 million. Sees FY2012 EPS of $0.62 - $0.68, versus prior guidance of $0.72 - $0.78 and the consensus of $0.75 and revenue of $152 - $157 million, versus prior guidance of $165 - $170 million and the consensus of $171.68 million.
CAMAC Energy Inc. (AMEX: CAK) 20.5% HIGHER; reported profit of 1 cent per share for its third quarter, from a break even result last year.
Roundys (NYSE: RNDY) 19.9% LOWER; reported Q3 EPS of $0.20, $0.06 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $973.6 million versus the consensus estimate of $980.28 million.
Sequenom, Inc. (Nasdaq: SQNM) 19.8% HIGHER; reported Q3 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $22.85 million versus the consensus estimate of $23.31 million. Also, the company announced that on November 2, 2012 the U.S. Patent & Trademark Office issued a Notice of Allowance for a U.S. patent covering novel methods for the use of massively parallel sequencing to detect fetal aneuploidies, such as Trisomy 21. Sequenom has licensed the exclusive rights to the invention, which was made by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong . The Notice of Allowance was issued in connection with U.S. patent application no. 12/178,181.
Ubiquiti Networks (Nasdaq: UBNT) 19.5% HIGHER; reported Q1 EPS of $0.15, $0.01 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $61.5 million versus the consensus estimate of $65.65 million. Sees Q2 2013 EPS of $0.17 - $0.20, versus the consensus of $0.17. Sees Q2 2013 revenue of $70 - $78 million, versus the consensus of $69.12 million.
Cytori Therapeutics (Nasdaq: CYTX) 19.3% HIGHER; reported Q3 net loss of 19 cents per share, or $11.2 million.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Kayak Software Corp. (Nasdaq: KYAK) 27.1% HIGHER; will be acquired by priceline.com (Nasdaq: PCLN) for $40 per share.
Groupon (Nasdaq: GRPN) 27.0% LOWER; reported Q3 EPS of $0.00, $0.03 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $568.6 million versus the consensus estimate of $590.12 million. Sees Q4 2012 revenue of $625-675 million, versus the consensus of $633.87 million.
DTS, Inc. (Nasdaq: DTSI) 27.0% LOWER; reported Q3 EPS of ($0.61), $0.68 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $22.2 million versus the consensus estimate of $24.97 million.
Sciclone Pharmaceuticals, Inc. (Nasdaq: SCLN) 23.3% LOWER; reported Q3 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $40.7 million versus the consensus estimate of $44.8 million. Sees FY2012 EPS of $0.62 - $0.68, versus prior guidance of $0.72 - $0.78 and the consensus of $0.75 and revenue of $152 - $157 million, versus prior guidance of $165 - $170 million and the consensus of $171.68 million.
CAMAC Energy Inc. (AMEX: CAK) 20.5% HIGHER; reported profit of 1 cent per share for its third quarter, from a break even result last year.
Roundys (NYSE: RNDY) 19.9% LOWER; reported Q3 EPS of $0.20, $0.06 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $973.6 million versus the consensus estimate of $980.28 million.
Sequenom, Inc. (Nasdaq: SQNM) 19.8% HIGHER; reported Q3 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $22.85 million versus the consensus estimate of $23.31 million. Also, the company announced that on November 2, 2012 the U.S. Patent & Trademark Office issued a Notice of Allowance for a U.S. patent covering novel methods for the use of massively parallel sequencing to detect fetal aneuploidies, such as Trisomy 21. Sequenom has licensed the exclusive rights to the invention, which was made by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong . The Notice of Allowance was issued in connection with U.S. patent application no. 12/178,181.
Ubiquiti Networks (Nasdaq: UBNT) 19.5% HIGHER; reported Q1 EPS of $0.15, $0.01 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $61.5 million versus the consensus estimate of $65.65 million. Sees Q2 2013 EPS of $0.17 - $0.20, versus the consensus of $0.17. Sees Q2 2013 revenue of $70 - $78 million, versus the consensus of $69.12 million.
Cytori Therapeutics (Nasdaq: CYTX) 19.3% HIGHER; reported Q3 net loss of 19 cents per share, or $11.2 million.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Unusual 11 Mid-Day MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
